If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-02. Numbers and descriptions here follow the published literature rather than marketing material.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Quantities of liquids are measured in units of volume. These include the SI unit cubic metre (m3) and its divisions, in particular the cubic decimeter, more commonly called the litre (1 dm3 = 1 L = 0.001 m3), and the cubic centimetre, also called millilitre (1 cm3 = 1 mL = 0.001 L = 10−6 m3). The volume of a quantity of liquid is fixed by its temperature and pressure. Liquids generally expand when heated, and contract when cooled. Water between 0 °C and 4 °C is a notable exception. On the other hand, liquids have little compressibility. Water, for example, will compress by only 46.4 parts per million for every unit increase in atmospheric pressure (bar). At around 4000 bar (400 megapascals or 58,000 psi) of pressure at room temperature water experiences only an 11% decrease in volume. Incompressibility makes liquids suitable for transmitting hydraulic power, because a change in pressure at one point in a liquid is transmitted undiminished to every other part of the liquid and very little energy is lost in the form of compression. However, the negligible compressibility does lead to other phenomena. The banging of pipes, called water hammer, occurs when a valve is suddenly closed, creating a huge pressure-spike at the valve that travels backward through the system at just under the speed of sound. Another phenomenon caused by liquid's incompressibility is cavitation. Because liquids have little elasticity they can literally be pulled apart in areas of high turbulence or dramatic change in direction, such as the trailing edge of a boat propeller or a sharp corner in a pipe.
on radiation protection in medical X-ray equipment on radiation protection in shoe X-ray machines (of which about 850 were in operation in 1963; the last one was not decommissioned until 1990) on the radioactivity of luminous dials. Another 40 regulations followed. The monitoring of such facilities took many years due to a lack of personnel. From 1963, dosimeters were to be used for personal protection, but this met with great resistance. It was not until 1989 that an updated radiation protection law was passed, accompanied by radiation protection training for the people concerned.
=== Industrial radiography === During World War II, Van de Graaff had used the compact generator invented with Trump to detect defects in ship hulls and ordnance for the U.S. Navy. Drawing on this application, HVEC produced 2-MeV industrial X-ray generators for non-destructive testing of manufactured goods. These units, capable of detecting flaws in thick steel sections, weighed more than two tons and were designed to operate in industrial facilities. HVEC adapted these generators to output electron beams, selling a line of industrial radiography equipment and also renting sterilization services to other companies. In 1957, Ethicon, a medical subsidiary of Johnson & Johnson, purchased an HVEC linear accelerator to sterilize surgical sutures, the first commercial medial product to use radiation processing. Sales of e-beam processing machines picked up after HVEC introduced insulating core transformers. ICTs, operating in the lower-voltage 300 keV to 2.5 MeV range, were used for crosslinking polyethylene and other polymers. W. R. Grace's Cryovac division used radiation crosslinking to produce heat-shrinkable materials for food packaging. Other companies purchased ICTs for extended to wire and cable insulation, rubber vulcanization, auto paint, textile modification, and semiconductors.
Sources: en.wikipedia.org
=== Supercritical fluid in power generation === The efficiency of a heat engine is ultimately dependent on the temperature difference between heat source and sink (Carnot cycle). To improve efficiency of power stations the operating temperature must be raised. Using water as the working fluid, this takes it into supercritical conditions. Efficiencies can be raised from about 39% for subcritical operation to about 45% using current technology. Many coal-fired supercritical steam generators are operational all over the world. Supercritical carbon dioxide is also proposed as a working fluid, which would have the advantage of lower critical pressure than water, but issues with corrosion are not yet fully solved. One proposed application is the Allam cycle. Supercritical water reactors (SCWRs) are proposed advanced nuclear systems that offer similar thermal efficiency gains.
The glyoxylate cycle, a variation of the tricarboxylic acid cycle, is an anabolic pathway occurring in plants, bacteria, protists, and fungi. The glyoxylate cycle centers on the conversion of acetyl-CoA to succinate for the synthesis of carbohydrates. In microorganisms, the glyoxylate cycle allows cells to use two carbons (C2 compounds), such as acetate, to satisfy cellular carbon requirements when simple sugars such as glucose or fructose are not available. The cycle is generally assumed to be absent in animals, with the exception of nematodes at the early stages of embryogenesis. In recent years, however, the detection of malate synthase (MS) and isocitrate lyase (ICL), key enzymes involved in the glyoxylate cycle, in some animal tissue has raised questions regarding the evolutionary relationship of enzymes in bacteria and animals and suggests that animals encode alternative enzymes of the cycle that differ in function from known MS and ICL in non-metazoan species. Plants as well as some algae and bacteria can use acetate as the carbon source for the production of carbon compounds. Plants and bacteria employ a modification of the TCA cycle called the glyoxylate cycle to produce four carbon dicarboxylic acid from two carbon acetate units. The glyoxylate cycle bypasses the two oxidative decarboxylation reactions of the TCA cycle and directly converts isocitrate through isocitrate lyase and malate synthase into malate and succinate.
== Management == Oxygen therapy may assist with daily living. In case of idiopathic pulmonary fibrosis, certain medications like nintedanib and pirfenidone can help slow the progression. Lastly, lung transplants may help.
== External links == "Anatomy photo:21:st-1500". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. – "Mediastinum: Pericardium (pericardial sac)" thoraxlesson4 at The Anatomy Lesson by Wesley Norman (Georgetown University) (heartpericardium) Atlas image: ht_pericard2 at the University of Michigan Health System – "MRI of chest, lateral view"
Sources: en.wikipedia.org
=== Since 1983 === The current steps for the recognition of a miracle follow rules laid down in 1983 by the apostolic constitution Divinus perfectionis Magister. Changes to the previous system included reduction of the waiting period for opening a Cause to five years after the candidate's death, previously 50; halving the number of miracles required; and abolishing the office of "devil's advocate", whose task was always to argue against canonisation. The legislation establishes two procedural stages: the diocesan one and that of what is known as the Roman Congregation. The first takes place within the diocese where the allegedly miraculous event happened. The bishop opens the enquiry on the presumed miracle in which depositions of the eyewitnesses questioned by a duly constituted court are gathered, as well as the complete clinical and instrumental documentation inherent to the case. In the second, the Congregation examines the documents sent and eventual supplementary documentation, pronouncing its judgment on the matter. The miracle may go beyond the possibilities of nature either in the substance of the fact or in the subject, or only in the way it occurs. The Dicastery distinguishes three degrees of miracles. The first degree is represented by resurrection from the dead (quoad substantiam).
Many metals such as the alkali metals react directly with the electronegative halogens gases to form salts. Solid salts can form upon evaporation of solvent from their solutions once the solution is supersaturated and the solid compound nucleates. This process occurs widely in nature and is the means of formation of the evaporite minerals. Insoluble salts can be precipitated by mixing two solutions, one containing the cation and one containing the anion. Because all solutions are electrically neutral, the two solutions mixed must also contain counterions of the opposite charges. To ensure that these do not contaminate the precipitated salt, it is important to ensure they do not also precipitate. If the two solutions have hydrogen ions and hydroxide ions as the counterions, they will react with one another in what is called an acid–base reaction or a neutralization reaction to form water. Alternately the counterions can be chosen to ensure that even when combined into a single solution they will remain soluble as spectator ions. If the solvent is water in either the evaporation or precipitation method of formation, in many cases the ionic crystal formed also includes water of crystallization, so the product is known as a hydrate, and can have very different chemical properties compared to the anhydrous material. Molten salts will solidify on cooling to below their freezing point. This is sometimes used for the solid-state synthesis of complex salts from solid reactants, which are first melted together.
Baker has co-founded several biotechnology companies, including Prospect Genomics which was acquired by an Eli Lilly subsidiary in 2001, Icosavax which was acquired by AstraZeneca in 2023, Sana Biotechnology, Lyell Immunotherapeutics, Xaira Therapeutics and GenBio AI.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.